Quantcast

Latest Treatment of schizophrenia Stories

2008-06-23 03:00:06

VENICE, Italy, June 23 /PRNewswire-FirstCall/ -- Results from olanzapine long-acting injection (LAI) clinical trials showed that the efficacy and safety profile of olanzapine LAI was generally consistent with that of Zyprexa(R) (olanzapine) with the exception of injection-related events. Results from a 24-week maintenance study (HGKA) and interim findings from an ongoing open-label study (HGKB) were presented at the first annual Schizophrenia International Research Society (SIRS) Conference...

2008-06-16 09:01:20

ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints. Neither dose of ACP-104 demonstrated improved efficacy as compared to placebo. The most common adverse events in the treatment arms relative to placebo were increased salivation, tachycardia, and dyspepsia, which were noted to be dose-related. There...

2007-05-22 15:00:49

SAN DIEGO, May 22 /PRNewswire/ -- Poor insight, previous failure to take medication and previous discontinuation of medication are the most common reasons for failing to take medication prescribed for schizophrenia in approximately two out of three patients, according to new results from the National Adherence Initiative in Schizophrenia survey, presented today at the 160th Annual Meeting of the American Psychiatric Association.(1) The survey involved over 13,000 patients with...

2007-05-22 15:00:49

SAN DIEGO, May 22 /PRNewswire/ -- After administration of paliperidone extended-release (ER) tablets, blood levels of the drug were not affected when given with a common antidepressant, according to new data presented today at the 160th Annual Meeting of the American Psychiatric Association. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is an antidepressant known to interact with several antipsychotic medications. This new study showed there was no clinically significant...

2005-09-19 16:10:26

A large study funded by NIH's National Institute of Mental Health (NIMH) provides, for the first time, detailed information comparing the effectiveness and side effects of five medications "“ both new and older medications "“ that are currently used to treat people with schizophrenia. Overall, the medications were comparably effective but were associated with high rates of discontinuation due to intolerable side effects or failure to adequately control symptoms. One new...

2005-08-15 23:10:00

By Anne Harding NEW YORK (Reuters Health) - So-called atypical antipsychotic drugs are just as likely as older antipsychotics drugs to cause movement disorders in older people with dementia, according to a new study. The findings underscore the importance of discussing the potential side effects of these drugs with patients and their caregivers before they are prescribed, Dr. Philip E. Lee of the University of British Columbia in Vancouver told Reuters Health. "A lot of people felt that they...